| Business Summary | | Avanir
Pharmaceuticals
is
an
emerging
specialty
pharmaceuticals
and
antibody
generation
services
company
engaged
in
the
discovery,
development
and
licensing
of
therapeutic
products
to
treat
chronic
human
diseases.
In
July
2000,
the
United
States
Food
and
Drug
Administration
approved
the
new
drug
application
for
the
Company's
lead
therapeutic
product,
docosanol
10%
cream,
a
topical
treatment
for
recurrent
oral-facial
herpes
infections,
commonly
known
as
cold
sores
and
fever
blisters.
SmithKline
Beecham
began
manufacturing
and
distributing
docosanol
10%
cream
for
the
Company
in
the
United
States
under
the
trade
name
Abreva
in
October
2000
under
an
exclusive
license
agreement
for
the
North
American
market. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Avanir
Pharmaceuticals
is
a
developmental
stage
company
organized
to
discover,
develop,
and
market
novel
therapeutic
products
to
treat
human
diseases.
For
the
nine
months
ended
6/30/01,
total
revenues
rose
from
$1.2
million
to
$7.8
million.
Net
loss
applicable
to
Common
fell
80%
to
$1.6
million
Revenues
reflect
higher
sales
of
Abreva
and
an
increase
in
government
grant
and
interest
income.
Net
income
reflects
the
absence
of
$4.1
million
in
litigation
settlement
fees. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Gerald Yakatan, Ph.D., 58 Pres,
CEO | $316K | Gregory Hanson, 54 CFO,
VP-Fin., Sec. | 145K | J. David Hansen, 49 VP-
Commercial Devel. | 179K | James Berg, 49 VP
of Clinical and Regulatory Affairs | 135K | Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|